Results 281 to 290 of about 767,219 (291)

The Role of Nuclear Medicine in Predicting Treatment Response to Immunotherapy and Targeted Therapy in Hepatocellular Carcinoma: A Narrative Review. [PDF]

J Hepatocell Carcinoma
Tu H, Lin D, Chen C.
europepmc   +1 more source

Nanographene Oxide Attenuates Acute GVHD by Modulating Macrophage Polarization in a Xenogeneic Mouse Model

Advanced Science, EarlyView.
Nanographene oxide (NGO) attenuates graft‐versus‐host disease (GVHD) severity by inhibiting STAT1‐mediated M1 macrophage polarization and suppressing T‐cell activation. NGO‐primed macrophages (NGO‐Mac) further enhance regulatory T‐cell induction via IL‐10. Both NGO and NGO‐Mac therapies mitigate inflammation and immune pathology, offering cell‐free and
Aaron Yu, Hyun Sung Park, Dong‐Hoon Chae, Jae Han Park, Jiyoung Heo, Keonwoo Cho, Jiho Kim, Hyewon Lee, Sueyeon Jee, Chanwoo Kim, Soon Won Choi, Jaechul Ryu, Eun‐Hye Hur, Yunsuk Choi, Eun‐Ji Choi, Mi‐Kyung Oh, Hwa‐Yong Lee, Je‐Hwan Lee, Kyung‐Rok Yu   +18 more
wiley   +1 more source

Enhancing prognostic precision: exploring the role of lung immune prognostic index in immunotherapy-treated soft tissue sarcoma patients-a retrospective study. [PDF]

J Orthop Surg Res
Sun M, Kang H, Luo Y, Zhou Y, Wang Y, Tang F, Lu M, Min L.   +7 more
europepmc   +1 more source

Neoantigen immunotherapy: a novel treatment for bladder cancer

Runxin Lv, Zhenzhu Liu, M. Lv, Yuze Song, Junlin Wang, Hui-Jun Mu, Yu Zhang, Xuejian Wang   +7 more
openalex   +1 more source

Efficacy and prognostic analysis of chemo-immunotherapy after TKI resistance in EGFR-mutant non-small cell lung cancer with TP53 or KRAS co-mutations. [PDF]

Front Immunol
Nie Y, Song C, Wu K, Yu M, Hu J, Liu S, Hui F.   +6 more
europepmc   +1 more source

From intracellular drivers to immune modulators: emerging paradigms in oncogenic pathway-directed immunotherapy optimization. [PDF]

Cell Commun Signal
Rao D, Wang T, Fu C, Luo Y, Lu J, Sun Z, Yan W, Liang H, Xia L, Huang W.   +9 more
europepmc   +1 more source

Perioperative efficacy and safety of short-course radiotherapy combined with immunochemotherapy in proficient mismatch repair rectal cancer. [PDF]

Tech Coloproctol
Li Y, Du J, Zhuang M, Hu G, Qiu W, Wang X, Tang J.   +6 more
europepmc   +1 more source

Prognosis and treatment response stratification according to loss of proofreading (LOP) <i>POLE</i> variants. [PDF]

J Immunother Cancer
Maddalena G, Zeineddine FA, Chowdhury S, Zeineddine MA, Yousef AM, Bergamo F, Lonardi S, Yap TA, White MG, Overman MJ, Kopetz S, Shen JP.   +11 more
europepmc   +1 more source

The role of circadian genes in predicting immunotherapy response and survival outcomes in cancer patients. [PDF]

Discov Oncol
Wu C, Li Q, Yuan Y, Liu J, Wan L, Wang R.   +5 more
europepmc   +1 more source